Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer
- 27 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (14), 3608-3615
- https://doi.org/10.1158/1078-0432.ccr-20-0268
Abstract
Purpose: The recent emergence of radioligand therapies for cancer treatment has increased enthusiasm for developing new theranostic strategies coupling both imaging and cytotoxicity in the same entity. We evaluated if CUB domain containing protein 1 (CDCP1), a transmembrane protein highly overexpressed in human cancers, is a target for cancer theranostics. Experimental Design: The ectodomain of CDCP1 was targeted using radiolabeled forms of 4A06, a potent and specific recombinant human antibody that we developed. Imaging and antitumor assessment studies were performed in animal models of pancreatic cancer, including two PDX models we developed for this study. For antitumor assessment studies, the endpoints were death due to tumor volume >3000 mm3 or ≥20% loss in body weight. Specific tracer binding or antitumor effects were assessed with an unpaired, two-tailed Student's t test and survival advantages were assessed with a log rank (Mantel Cox) test. Results: 89Zr-4A06 detected a broad dynamic range of full length or cleaved CDCP1 expression on seven human pancreatic cancer tumors (n = 4/tumor). Treating mice with single or fractionated doses of 177Lu-4A06 significantly reduced pancreatic cancer tumor volume compared to mice receiving vehicle or unlabeled 4A06 (n = 8, P225Ac-4A06 also inhibited tumor growth, although the effect was less profound compared to 177Lu-4A06 (n = 8, P225Ac-4A06 (HR = 2.56, P <0.05). Conclusions: These data establish that CDCP1 can be exploited for theranostics, a finding with widespread implications given its breadth of overexpression in cancer.Keywords
Other Versions
Funding Information
- NIH (S10RR023051, S10OD012301)
- NCI (U24CA210974, R01CA222862, R01CA227807, R01CA239604, R01CA230263)
- V Foundation (A130433)
- NCI (1P41CA196276, CA191018)
- NIH (GM097316)
- American Cancer Society (130635-RSG-17-005-01-CCE)
- NIH (R01MH114053, R01EB025027)
This publication has 28 references indexed in Scilit:
- Trask Loss Enhances Tumorigenic Growth by Liberating Integrin Signaling and Growth Factor Receptor Cross-Talk in Unanchored CellsCancer Research, 2013
- Practical Theoretic Guidance for the Design of Tumor-Targeting AgentsMethods in Enzymology, 2012
- Roles of CUB domain‐containing protein 1 signaling in cancer invasion and metastasisCancer Science, 2011
- Proteolysis-induced N-terminal Ectodomain Shedding of the Integral Membrane Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Is Accompanied by Tyrosine Phosphorylation of Its C-terminal Domain and Recruitment of Src and PKCδOnline Journal of Public Health Informatics, 2010
- CUB Domain–Containing Protein 1, a Prognostic Factor for Human Pancreatic Cancers, Promotes Cell Migration and Extracellular Matrix DegradationCancer Research, 2010
- Standardized methods for the production of high specific-activity zirconium-89Nuclear Medicine and Biology, 2009
- The cell surface glycoprotein CDCP1 in cancer-Insights, opportunities, and challengesIUBMB Life, 2009
- Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lungCancer Science, 2009
- Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigenOncogene, 2003